Immunoglobulin heavy constant epsilon (IgE) (IgE)

Immunoglobulin E (IgE) is a specialized class of antibody that plays a central role in Type I hypersensitivity reactions and the immune response to parasitic infections. In atopic individuals, the immune system produces patient-specific IgE antibodies directed against otherwise harmless environmental allergens, such as pollen, dust mites, and animal dander. These IgE molecules bind with high affinity to the FcεRI receptor on the surface of mast cells and basophils, sensitizing them to the specific allergen. Upon subsequent exposure, the environmental allergens cross-link the receptor-bound IgE, triggering a signaling cascade that leads to the rapid release of inflammatory mediators like histamine and leukotrienes, which cause the symptoms of allergy and asthma. Therapeutic strategies targeting IgE, such as the monoclonal antibody omalizumab, aim to neutralize free IgE and prevent its binding to receptors, thereby blunting the allergic cascade. Recent advancements also explore targeting the IgE-producing B cells or destabilizing the IgE-receptor complex to provide more rapid and sustained relief.

Other names

Allergen-specific IgEsIgEIgE-allergen complexImmunoglobulin EIGHEImmunoglobulin heavy constant epsilon

Drugs targeting this molecule primarily work by binding to the Fc region of free IgE, specifically the Cε3 domain, to prevent its interaction with the high-affinity receptor FcεRI on mast cells and basophils. This neutralization reduces the density of IgE-FcεRI complexes on the cell surface, thereby increasing the threshold for allergen-induced degranulation. Some newer agents also target the Cε2 domain to destabilize existing IgE-receptor complexes or target IgE-producing B cells to reduce synthesis.